Inspire Pharmaceuticals

Piper Jaffray is discontinuing its coverage on Inspire Pharmaceuticals (NASDAQ: ISPH) as the company has been fully acquired by Merck & Co. (NYSE: MRK). Piper Jaffray most recently rated the stock at Neutral and held a $5 price target on the stock. Says Piper Jaffray, in the report, “Investors...

Deutsche Bank is out with its report today on Inspire Pharmaceuticals (NASDAQ: ISPH), raising its PT from $4 to $5, after Merck announced its agreement to acquire Inspire Pharmaceuticals. In a note to clients, Deutsche Bank writes, "Merck's proposed valuation is in line with our sum-of-the-parts...

Duncan-Williams is maintaining its Hold rating on shares of Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH). “We report that the FDA approved an ANDA for generic epinastine hydrochloride (Allergan's Elestat) on March 14,” Duncan-Williams writes. “The generic company receiving the first ANDA approval...

Deutsche Bank has published a research report on Inspire Pharmaceuticals (NASDAQ: ISPH) after downgrading the company to Hold from Buy yesterday. In the report, Deutsche Bank writes "Early Monday, we downgraded Inspire shares to Hold, following the announcement of negative results for TIGER-2, the...

Yesterday, Inspire announced that denufosol failed to meet its primary and secondary endpoints in the TIGER-2 Phase III study in cystic fibrosis (CF), Piper Jaffray reports. “We are downgrading Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) to a Neutral from an Overweight and lowering our price...

Piper Jaffray has downgraded Inspire Pharmaceuticals (NASDAQ: ISPH) from Overweight to Neutral and has lowered the price target from $10 to $4.

Piper Jaffray reports that on Monday, Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced that partner Santen Pharmaceuticals launched Diquas ophthalmic solution 3% (diquafosol) in Japan. “We believe the Diquas opportunity in Japan is meaningful for ISPH, with peak annual royalties of up to $25M...

Jefferies & Co. has published a research report for Inspire Pharmaceuticals Inc. (NASDAQ: ISPH) initiating coverage at Buy. In the report Jefferies writes "We believe Inspire's lead program, denufosol, will have statistically significant TIGER-2 data in 1Q:11, attain FDA approval in 2H:11, and...

Leerink Swann analyst Joseph P. Schwartz reiterated his Outperform rating for shares of Inspire Pharmaceuticals, Inc. (Nasdaq: ISPH) and raised the price target from $8 to $10. Swann discussed the implications of Inspire Pharmaceuticals' AzaSite product having entered into Phase II trials to treat...